IL1B and COVID-19: The incidence of HT among COVID-19 patients has sparked renewed interest among researchers, as these patients produce an excess of inflammatory cytokines (IL-6, IL-1β, IFN-γ, TNF-α) (Mohammadi et al., 2023).